Symbiotics - Asset Management

Symbiotics is the best partner to professional and qualified investors that
want to own impact investments highly decorrelated to other asset classes.


– Alexandre Prautzsch, Head of Clients Division –

Investment Funds

You are an investor following sustainability principles and pursuing development impact goals, with a particular interest in emerging and frontier markets. We offer a range of investment funds (whether fixed income, high yield or equity) that could hopefully fit your needs.

Customized Mandates

You are a bank, a fund promoter or a professional investor looking to set-up your own investment products or mandate following sustainability principles and development impact goals. We offer a range of customized solutions, including private label funds, managed accounts and single investor mandates.


Investment Funds

The Regional MSME Investment Fund for Sub-Saharan Africa (REGMIFA)


Customized Mandates

“Symbiotics historically specializes in customizing impact investing funds for private banks, development finance institutions (DFIs), fund promoters as well as large institutional asset owners. We are today the leader in number of funds managed in impact investing”


– Valérie Dujardin, Head of Portfolios Division –

A public private partnership impact fund dedicated to Sub-Saharan Africa

Initiated jointly by KfW Entwicklungsbank and International Finance Corporation (IFC), the Regional Micro Small and Medium Enterprise Investment Fund for Sub-Saharan Africa (REGMIFA) is a multilayer fund launched in 2010 with over USD 200 million commitments from 13 Development banks. Although operating in a challenging economic context, returns have been positive and in line with investor impact expectations, reaching out to numerous MSME financial institutions across sub-Saharan Africa.

A single institutional investor fund dedicated to microfinance in emerging and frontier markets

Launched in 2013, this customized open ended fund was structured for a large institutional investor who had decided to place more than USD 100 million in social impact investments. Given its low level of cash and low cost structure, this single investor fund has been outperforming industry benchmarks.


For legal reasons, access to information concerning the funds is limited to persons residing in a country where the funds are authorised for sale. The information contained in this site must under no circumstances be construed as a solicitation to buy or sell shares in these funds. To continue, please select your country of residence:

Are you a


I hereby confirm that I am a qualified investor according to Art 10 para. 3 bis of the Swiss Federal Collective Investment Schemes Act (CISA).

Are you a


By confirming that I am an investment professional/professional client, Symbiotics UK Ltd will treat the user as having accepted and understood the FCA’s definition under the UK regulatory system, which may be found at the following link: To the best of my knowledge, after due enquiry, I am permitted by the laws of my jurisdiction of residence to access this site and the information contained herein.

The information on this website has been issued by Symbiotics SA.

This website is directed exclusively to Swiss qualified investors as defined in Art. 10 of the Swiss Collective Investment Schemes Act of 23 June 2006 as amended on 1 June 2013(the “CISA”) and its implementing regulations,especially the Collective Investment Schemes Ordinance of 22 November 2006as amended on 1 March 2013 (the “CISO”) and is not for distribution to retail customers. The investment products referred to on the following pages have not been approved for distribution to non qualified investors in or from Switzerland by the Swiss Financial Market Supervisory Authority (FINMA). Accordingly, units of such investment products and information, documents or material pertaining to these investment products on the following pages may only be distributed in or from Switzerland to qualified investors. The agreement to this legal disclaimer doesn’t constitute an evidence according to art. 6 para.1 or 5 CISO nor a written declaration according to art. 6a CISO.

The information and material are provided for information purposes only and are not to be used or considered to be an offer or solicitation to buy, sell or subscribe to any investment products.

Any information contained on this website does not constitute the investment policy of Symbiotics SA or an investment recommendation, but merely the different assumptions, views and analytical methods of the analysts who prepared it. Furthermore, the information, opinions and estimates expressed herein reflect a judgment as of its original publication date and are subject to change without notice.

The information and opinions presented by Symbiotics SA analysts have been obtained from sources believed to be reliable. Although all reasonable care was taken in gathering the information and formulating the opinions contained herein, Symbiotics SA does not make any representation or warranty (including liability towards third parties) as to its accuracy or completeness. Accordingly, Symbiotics SA accepts no liability for any loss arising from the use of this website, which has been made available for information purposes only.

The information included on this website does not take into consideration the specific investment objectives, financial situation or particular needs of any person who may read it and invest in any investment product. Symbiotics SA has not taken any steps to ensure that any investments referred to are suitable for any particular investor. Any reports are not to be relied upon in substitution for the exercise of independent judgment. The value and income of any of the investment products mentioned in this document can vary upwards as well as downwards. The market value may be affected by changes in economic, financial or political factors, time to maturity, market conditions and volatility, or the credit quality of any issuer or reference issuer.

Furthermore, foreign currency rates may have a positive or adverse effect on the value, price or income of any security or related investment mentioned. Many factors may affect the value of a financial instrument, and accordingly, investors effectively assume all risks and may receive back less than they had originally invested. Any investors interested in subscribing inany investment product should conduct their own investigation and analysis of the instrument as to the risks involved in transactions on such investment product. Past performance should not be taken as an indication or guarantee of future performance and no representation or warranty, expressed or implied, is made by Symbiotics SA regarding future performance.

This web-site, including without limitation all documents that may be made available through it from time to time (including, inter alia, term-sheet, fact-sheet is intended for professional clients and eligible counterparties only; not for retail clients.

This web-site is made available by Symbiotics (UK) Limited (“SUKL”) unless otherwise stated. SUKL is authorised and regulated by the Financial Conduct Authority in the UK (“FCA”), firm reference number 616299.

Access to this site is only directed at/intended for those in jurisdictions where the use of this site is permitted by law/regulation.

Persons who wish to access this site are required by SUKL to inform themselves about and to observe any legal or regulatory restrictions which may affect their eligibility to access the site or to subscribe for interests in the investment products. Professional advice should be sought in case of doubt.

Neither this web-site, nor any document made available through it, is intended to constitute.

Thank you for your interest

For legal reasons we cannot provide you any information regarding our products and services.

For more information please contact us at or give us a call at +41 22 338 15 40.

Thank you for your understanding.